EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Harnessing Repurposed Drugs to Enhance Temozolomide Efficacy in Glioblastoma

Ali Nakhaei iD, Atefeh Taghavi, Amir R Afshari iD, Farzaneh Davoudi, Elaheh Gheybi, Mohammad Jalili-Nik iD

Cancer Reports · 2026

DOI: 10.1002/cnr2.70643 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Reports, 2026. Verfasst von Ali Nakhaei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, MMS.C, Islamic Azad University, Mashhad, Iran. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Temozolomide, Drug Repositioning. Die Arbeit nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma (GB) is the most aggressive primary malignant brain tumor in adults and remains associated with poor survival despite surgical resection followed by radiotherapy and temozolomide (TMZ) chemotherapy. Intrinsic and acquired resistance to TMZ, including MGMT‐dependent DNA repair and activation of pro‐survival pathways, could decrease treatment efficacy. Drug repurposing offers an attractive strategy to identify agents that may enhance TMZ activity because these drugs already have known pharmacokinetic and safety profiles. This narrative review summarizes the available evidence on repurposed drugs investigated as potential modulators of TMZ response in GB. Recent Findings A range of repurposed agents, including chloroquine, valproic acid, levetiracetam, metformin, aspirin, amlodipine, atorvastatin, chlorpromazine, melatonin, disulfiram, bortezomib, and verteporfin, have been evaluated in GB models and selected clinical studies. Reported mechanisms include modulation of MGMT expression, autophagy, oxidative stress, apoptosis, DNA‐damage responses, cancer stem‐cell properties, and signaling pathways such as PI3K/AKT/mTOR, AMPK, EGFR, STAT3, ERK1/2, and NF‐κB. Several agents have enhanced TMZ‐associated cytotoxicity in cell culture and animal models. However, clinical evidence remains limited, and the results are inconsistent for some drugs. Blood–brain barrier penetration, achievable intratumoral drug exposure, toxicity, treatment scheduling, and molecular heterogeneity of GB remain major translational challenges.

Conclusion

Repurposed drugs may provide useful candidates for improving TMZ‐based therapy in GB. However, most evidence remains preclinical, and further studies are needed to clarify blood–brain barrier penetration, optimal dosing, toxicity, predictive biomarkers, and clinical efficacy. Well‐designed prospective clinical trials are required before these combinations can be incorporated into routine GB treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsTemozolomideDrug RepositioningAntineoplastic Agents, AlkylatingAntineoplastic Combined Chemotherapy ProtocolsHumansAnimalsDrug Resistance, NeoplasmSignal Transduction

Stichwörter der Autor:innen

FDA‐approvedTemozolomidechemotherapy resistancedrug repurposingglioblastoma

Substanzen

TemozolomideAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Student Research Committee, MMS.C, Islamic Azad University, Mashhad, Iran.
  • Department of Basic Sciences, Faculty of Medicine, Mashhad Medical Sciences, Islamic Azad University, Mashhad, Iran.
  • Bahman Educational and Medical Charity Hospital, Mashhad, Iran.
  • Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Biology, School of Computer, Mathematical, and Natural Sciences, Morgan State University, Baltimore, Maryland, USA.
  • Pharmacological Research Center of Medicinal Plants, Basic Science Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

ORCID-Profile: Ali Nakhaei, Amir R Afshari, Mohammad Jalili-Nik

Zitieren

APA

Nakhaei, A., Taghavi, A., Afshari, A. R., Davoudi, F., Gheybi, E., & Jalili-Nik, M. (2026). Harnessing Repurposed Drugs to Enhance Temozolomide Efficacy in Glioblastoma. Cancer Reports. https://doi.org/10.1002/cnr2.70643

Vancouver

Nakhaei A, Taghavi A, Afshari AR, Davoudi F, Gheybi E, Jalili-Nik M. Harnessing Repurposed Drugs to Enhance Temozolomide Efficacy in Glioblastoma. Cancer Reports. 2026. doi:10.1002/cnr2.70643

BibTeX
@article{Nakhaei2026,
  author = {Nakhaei, Ali and Taghavi, Atefeh and Afshari, Amir R and Davoudi, Farzaneh and Gheybi, Elaheh and Jalili-Nik, Mohammad},
  title = {Harnessing Repurposed Drugs to Enhance Temozolomide Efficacy in Glioblastoma},
  journal = {Cancer Reports},
  year = {2026},
  doi = {10.1002/cnr2.70643}
}
Kostenlos starten →